INDIVIDUAL TEST 960
MuSK Antibodies (IgG)
IndicationSuspicion of myasthenia gravis.MethodRadioimmunoprecipitation with a recombinant antigen.AnswerThe result is given as a negative or positive with a value (nmol/L).InterpretationAntibodies against MuSK (muscle-specific kinase, is a receptor tyrosine kinase) are seen in approximately 40% of patients with myasthenia gravis lacking AChR (acetylcholine receptor) antibodies. MuSK is a membrane protein in motor end plates and is important for the structure and function of AChR.ReferencesPirskanen-Matell R., G. Matell, B. Kalb, S. Bjelak. (2000). Myasthenia gravis – en autoimmun neuromuskulär sjukdom. Läkartidningen 45:4594-4598.
Rostedt Punga A. (2013). Nya forskningsrön ökar förståelsen av Myastenia Gravis. Neurologi i Sverige, nr 2-13: 16-21.
Matthews I. et. al. (2004). Muscle-specific receptor tyrosine kinase autoantibodies – a new immunoprecipitation assay. Clinica Chimica Acta 348:95-99. PMID: 15369741
Hoch W. et. al. (2001). Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acethylcholine receptor antibodies. Nature Medicine. 7:365-368. PMID: 11231638.
Meriggioli MN. et. al. (2009). Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet neurology. 8:475-490. PMID: 19375665.
Skeie GO, et. al.: European Federation of Neurological Societies. (2010) Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. Jul;17(7):893-902. PMID: 20402760.
Can't find what you're looking for? We are here to help
ENSKILD ANALYS 960
MuSK-antikroppar (IgG)
IndikationMisstanke om myastenia gravis.MetodRadioimmunoprecipitation med rekombinant antigen.SvarResultatet anges som negativt eller positivt. Positivt resultat följs åt med koncentration (nmol/L).TolkningAntikroppar mot MuSK ses hos ca 40% av de patienter med myastenia gravis som saknar AChR-antikroppar. MuSK är ett membranprotein i motoriska ändplattor och har betydelse för uppbyggnad och funktion av AChR.ReferenserPirskanen-Matell R., G. Matell, B. Kalb, S. Bjelak. (2000). Myasthenia gravis – en autoimmun neuromuskulär sjukdom. Läkartidningen 45:4594-4598.
Rostedt Punga A. (2013). Nya forskningsrön ökar förståelsen av Myastenia Gravis. Neurologi i Sverige, nr 2-13: 16-21.
Matthews I. et. al. (2004). Muscle-specific receptor tyrosine kinase autoantibodies – a new immunoprecipitation assay. Clinica Chimica Acta 348:95-99. PMID: 15369741
Hoch W. et. al. (2001). Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acethylcholine receptor antibodies. Nature Medicine. 7:365-368. PMID: 11231638.
Meriggioli MN. et. al. (2009). Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet neurology. 8:475-490. PMID: 19375665.
Skeie GO, et. al.: European Federation of Neurological Societies. (2010) Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. Jul;17(7):893-902. PMID: 20402760.